Navigation Links
Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor,Tanespimycin (KOS-953) at AACR

Tanespimycin Shown to Have No Effect on QTc Interval

HAYWARD, Calif., April 16, 2007 /PRNewswire/ -- Kosan Biosciences Incorporated today presented safety data from preclinical and clinical studies of its lead Hsp90 inhibitor, tanespimycin (KOS-953). Serial electrocardiogram (ECG) monitoring of patients was conducted in four Phase 1 trials of tanespimycin. Cardiac monitoring analyses were conducted in more than 85 patients. Tanespimycin was found to have no effect on QTc interval (a measure of the heart's electrical cycle) in these patients based on data analyses from manually read ECGs in a central laboratory or by site cardiologists.

"The analyses performed by cardiac specialists confirm that tanespimycin had no effect on QTc interval," said Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and Chief Executive Officer. "Moreover, it is clear from these analyses that two previously reported incidents of possible QTc interval effects in studies of tanespimycin conducted by the National Cancer Institute's (NCI) Cancer Therapy Evaluation Program (CTEP) were based on artifactual QTc prolongation data from automated computer reads and were unrelated to drug product. Our Hsp90 inhibitors have been administered to more than 600 patients in trials conducted by Kosan and by the NCI and the safety profile of the compound class has been well characterized. With the anticipated initiation of our TIME registration program for tanespimycin in patients with multiple myeloma, and with plans underway to advance second- generation alvespimycin into later-stage trials in patients with HER2-positive metastatic breast cancer, we look forward to further characterizing the efficacy and safety profiles of these exciting and potentially important new cancer therapies."

The data from the cardiac monitoring analyses were presented at the 2007 Annual Meeting of the American Association for Cancer Research (AACR) in a p
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
(Date:8/22/2014)... Cali ., Aug. 22, 2014  Research presented ... that a therapy being developed by Hera Therapeutics Inc. combats ... 70 percent of all cervical cancer. When tested ... of HPV-16, HPV-18 and HPV-11 cells, according to Louise ... who presented the findings at the Seattle ...
(Date:8/22/2014)... , Aug. 22, 2014  Cannabis Science, ... cannabis formulation-based drug development and related consulting, is ... third international medical cannabis conference taking place at ... France , on October 22, 2014.  The ... stakeholders, such as researchers, health professionals, and patients, ...
(Date:8/22/2014)...  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced the ... common stock and warrants at a price of $10,000 ... to deducting underwriting discounts and commissions and offering expenses ... immediately separable and will be issued separately.  The shares ... The NASDAQ Stock Market under the ticker symbol "WGBS" ...
Breaking Medicine Technology:Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4
... 2011 Sigma-Aldrich Corporation (NASDAQ: SIAL ) ... unit, SAFC® ( www.safcglobal.com ), is introducing a novel ... (CHO) cell line. Designed for use in the production ... the first commercially available glutamine synthetase (GS) knockout CHO ...
... YORK, Oct. 27, 2011 Reportlinker.com ... report is available in its catalogue: ... Reimbursement Outlook: Optimizing price and market ... http://www.reportlinker.com/p0165652/Pharma-Pricing-and-Reimbursement-Outlook-Optimizing-price-and-market-access-in-a-recessionary-climate.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Health_Insurance ...
Cached Medicine Technology:SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 2SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 3SAFC Introduces the First Commercially Available Novel CHOZN® GS Knockout CHO Cell Line 4Pharma Pricing and Reimbursement Outlook: Optimizing price and market access in a recessionary climate 2Pharma Pricing and Reimbursement Outlook: Optimizing price and market access in a recessionary climate 3Pharma Pricing and Reimbursement Outlook: Optimizing price and market access in a recessionary climate 4Pharma Pricing and Reimbursement Outlook: Optimizing price and market access in a recessionary climate 5
(Date:8/22/2014)... Las Vegas, NV (PRWEB) August 22, 2014 ... that teaches readers how they can use natural methods ... for years has caught the attention of Shane Michaels, ... only a condition that affects the skin, it can ... suffer from it,” reports Michaels. “The intense itching and ...
(Date:8/22/2014)... receptor (EGFR) mutations found in the circulating free tumor ... lung cancer (NSCLC) patients correlates well with the EGFR ... kinase inhibitor (TKI) therapy is approved for EGFR activating ... for determining mutation status is with DNA derived directly ... available. A more abundant and less invasive source of ...
(Date:8/22/2014)... Advancements in ultrasound technologies make ... due to their cost-effectiveness, non-invasiveness, and absence of ... such as the evolution of wireless transducers and ... market moving throughout 2014 and beyond. Such Ultrasound’s ... only the point-of-care (POC) testing in hospital settings, ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 CarePoint ... specialist in Internal Medicine, Geriatrics, Hospice and Palliative ... CarePoint Health Medical Group. Their system welcomes Dr. ... and experienced physicians comprise CarePoint Health Medical Group, ... in Hudson County, representing a wide range of ...
(Date:8/22/2014)... West Orange, NJ. August 22, 2014. A ... shows that persons with multiple sclerosis (MS) may ... cognitive rehabilitation. The study was epublished ahead of ... (Yael Goverover, Helen Genova, Hali Griswold, Nancy D. ... awareness in persons with multiple sclerosis doi: 10.3233/NRE-141113). ...
Breaking Medicine News(10 mins):Health News:Beat Eczema: Review Exposes Susan Clark’s Guide to Curing Eczema Naturally 2Health News:High concordance between EGFR mutations from circulating-free tumor DNA and tumor tissue in non-small cell lung cancer 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 3Health News:Dr. Reisner Joins CarePoint Health Medical Group 2Health News:Kessler Foundation study of self-awareness in MS has implications for rehabilitation 2
... for study of human genetics and disease , THURSDAY, Aug. ... genes are responsible for all seven types of coats found ... like Bo, President Obama,s pooch, or long-haired like Lassie, variations ... to a U.S. National Institutes of Health study published online ...
... disparity in prostate cancer stage at diagnosis has decreased ... published online August 27 in the Journal of ... from the Surveillance, Epidemiology, and End Results (SEER) program, ... New Jersey and the University of Medicine and Dentistry ...
... RICHMOND, Va., Aug. 27 The ,Help is Here ... week of August 31 - September 3 at various cities ... on programs that provide prescription medicines for free or nearly ... - and having risen for 26 straight months - the ...
... ,fatostatin, is still in early stages , THURSDAY, Aug. 27 ... to have the power to turn off fat production, potentially ... injected with the chemical, known as fatostatin, didn,t get fatter ... team said. , But don,t run out and ask ...
... , MINNEAPOLIS, Aug. 27 In August 1989, a ... to become one of the first child advocacy centers in the ... organization, improving the way child abuse is investigated around the world. ... medical examinations for children and vulnerable adults who report sexual abuse ...
... The Radiological Society of North America (RSNA) reaffirmed ... a study and accompanying perspective on radiation dose from ... of Medicine (NEJM). In "Exposure to ... M.D., M.Sc., and colleagues reported that imaging procedures are ...
Cached Medicine News:Health News:Benji, Marley or Bo: Three Genes Dictate Dog's Coat 2Health News:Partnership for Prescription Assistance Prepared To Help Virginia Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared To Help Virginia Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared To Help Virginia Workers Hurt by Recession 4Health News:Fat-Fighting Chemical Holds Promise 2Health News:Minneapolis-based CornerHouse Marks 20th Anniversary of Helping Sexually Abused Children Around the World 2Health News:Minneapolis-based CornerHouse Marks 20th Anniversary of Helping Sexually Abused Children Around the World 3Health News:Radiologists, medical physicists work to make imaging procedures safer 2
... The 1081 is an all-in-one drape ... The drape includes a pouch with filter ... finger cot. 64 inches (164cm) TUR ... Elastic aperture, Neoprene finger cot, Fluid collection ...
... Both the Penilab IV and the Penilab V ... studies. Model 1060 is similar to the Model ... nor can one be added later. The Penilab ... including all of the accessories you'll need to get ...
The Model 240 is a single-channel instrument designed for penile tumescence monitoring. It features exceptional stability. It's ready for use with most multi-channel recorders having a DC input....
... II SP MRI-Compatible Anesthesia System is perfect for ... than one type of anesthetic agent. , ... due to its wider stance, has a larger ... bellows assembly is utilized in both the Integra ...
Medicine Products: